INVESTOR FAQs

1.
What is BioRestorative Therapies (“BRT”)?

BioRestorative Therapies, Inc. ("BRT"), develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells, including:

 

• brtxDISC™ (Disc Implanted Stem Cells), BRT’s lead therapeutic product, is a mesenchymal stem cell product derived from autologous human bone marrow. It is to be used in an investigational non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease and is intended for patients who have failed non-invasive procedures and potentially face the prospect of surgery. The treatment, utilizing brtxDISC™, involves culturing a patient’s own stem cells and then delivering them to the damaged disc in an outpatient procedure.

 

• ThermoStem® is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.

 

 

2.
What is BioRestorative Therapies stock symbol?

The Company’s common stock trades under the stock symbol “BRTX” and is listed on the OTCBB exchange.

3.
How many common shares of BioRestorative Therapies are outstanding?

As of December 31, 2014, there were 33,923,179 shares of the issuer's common stock outstanding.

4.
Where is BioRestorative Therapies headquartered?
Our corporate address is:
            BioRestorative Therapies, Inc.
                    40 Marcus Drive
                    Suite One
    Melville, New York 11747
5.
How can I buy or sell BioRestorative Therapies common stock?

The Company’s common stock can be purchased or sold through any registered broker or through an online trading account.

6.
Does BioRestorative Therapies offer a direct share purchase plan?

The Company does not offer a direct share purchase plan at this time.

7.
Does BioRestorative Therapies issue dividends or have a DRIP program?

The Company does not issue dividends or have a DRIP program at this time.

8.
Where can I obtain additional information on BioRestorative Therapies?

Company’s press releases, annual reports, quarterly reports and other materials can be accessed through our website under Investor Relations.  

9.
Who is BioRestorative Therapies’ transfer agent and how does a registered shareholder contact the agent regarding account information?

The transfer agent for the common stock is:  Island Stock Transfer (www.islandstocktransfer.com)

10.
How can I access SEC documents, such as a 10-K?
11.
When is BioRestorative Therapies’ fiscal year end?

BioRestorative Therapies’ fiscal year end is December 31.

12.
Who is BioRestorative Therapies’ independent auditor?
Marcum LLP
750 Third Avenue
New York, NY 10017
13.
Who is BioRestorative Therapies’ General Counsel?
Certilman Balin Adler & Hyman, LLP
90 Merrick Avenue
East Meadow, NY 11554
14.
How do I contact Investor Relations?
If you can't find the information you're looking for on our website, please feel free to contact:
 
BioRestorative Therapies, Inc.
Mandy Clyde
Vice President of Operations
Phone: (631) 760-8100
 
 
BioRestorative Therapies: A Stem Cell Biotechnology Company